Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Dicerna Pharmaceutic
(NQ:
DRNA
)
24.64
USD
UNCHANGED
Streaming Delayed Price
Updated: 5:01 PM EST, Jan 22, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Dicerna Pharmaceutic
< Previous
1
2
3
4
5
6
7
8
9
Next >
Dicerna to Participate in the H.C. Wainwright Virtual BioConnect Conference
January 05, 2021
Dicerna announced that Doug Fambrough will participate in two events at the H.C. Wainwright Virtual BioConnect Conference taking place Jan. 11-14.
From
Business Wire News Releases
Dicerna Announces Novo Nordisk’s Nomination of First Candidate for Development Under RNAi Discovery and Development Agreement and Additional Milestone Achievement
January 05, 2021
Dicerna announced that Novo Nordisk has nominated its first candidate for development under the existing agreement between the two companies.
From
Business Wire News Releases
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 04, 2021
Dicerna announced the Company approved the grant of inducement stock options of common stock and restricted stock units among three new employees.
From
Business Wire News Releases
Dicerna Announces Enrollment Completion of PHYOX™2 Pivotal Trial of Nedosiran for Treatment of Primary Hyperoxaluria
January 04, 2021
Dicerna today announced the enrollment completion of the PHYOX™2 pivotal trial of nedosiran for the treatment of primary hyperoxaluria.
From
Business Wire News Releases
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2020
Dicerna announced that the Company approved the grant of inducement stock options of common stock and restricted stock units among six new employees.
From
Business Wire News Releases
Dicerna Announces Positive Updated Data From Phase 1 Trial of RG6346 for Treatment of Chronic Hepatitis B Virus (HBV) Infection at AASLD’s The Liver Meeting® Digital Experience™ 2020
November 16, 2020
Dicerna announced positive updated Phase 1 data on its investigational GalXC™ RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV).
From
Business Wire News Releases
Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for First GalXC™ RNAi Candidate Under Companies’ Global Research Collaboration and Licensing Agreement
November 16, 2020
Dicerna announced FDA acceptance of the IND Application filed by Lilly for LY3561774, clinical-stage candidate to emerge from their collaboration.
From
Business Wire News Releases
Dicerna to Participate in Upcoming Investor Conferences
November 11, 2020
Dicerna announced that Douglas M. Fambrough, Ph.D., president and CEO, will be participating in fireside chats at two upcoming investor conferences.
From
Business Wire News Releases
Dicerna Presents New Nonclinical Research Highlighting the Application of its RNAi Technology in Extrahepatic Tissues at TIDES Europe 2020
November 10, 2020
Dicerna will present an update on the Company’s early-stage development of extrahepatic RNAi therapeutics at TIDES Europe 2020.
From
Business Wire News Releases
Dicerna Announces Third Quarter 2020 Financial Results and Provides a Business Update
November 05, 2020
Dicerna today reported its financial results for the third quarter ended Sep. 30, 2020.
From
Business Wire News Releases
WaterMill Asset Management Sends Letter to Ziopharm Oncology Shareholders
November 05, 2020
WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of...
From
Business Wire News Releases
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 02, 2020
Dicerna announced that the Company approved the grant of inducement stock options of common stock and restricted stock units among nine new employees.
From
Business Wire News Releases
Dicerna Announces Updated Phase 1 Data on RG6346 Investigational Treatment for Chronic Hepatitis B Virus to be Presented in Late-Breaking Session at AASLD’s The Liver Meeting® Digital Experience™ 2020
November 01, 2020
Dicerna will present updated data related to RG6346, an RNAi investigational therapy, at The Liver Meeting® Digital Experience™ 2020.
From
Business Wire News Releases
Dicerna to Report Third Quarter 2020 Financial Results on November 5, 2020
October 29, 2020
Dicerna announced that it will release its Q3 2020 financial results and will provide a general business update on Thursday, Nov. 5.
From
Business Wire News Releases
Dicerna Presents Positive New Interim Data From PHYOX™3 Long-Term, Open-Label Extension Study of Nedosiran for Treatment of Primary Hyperoxaluria (PH)
October 22, 2020
Dicerna announced positive new interim data from its ongoing PHYOX3 open-label trial of nedosiran, an investigational therapy for PH1, PH2 and PH3.
From
Business Wire News Releases
Dicerna to Participate in the H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference
October 13, 2020
Dicerna announced that Doug Fambrough will participate in a virtual fireside chat at the H.C. Wainwright HBV Mini-Conference on Tuesday, Oct. 20.
From
Business Wire News Releases
VBL Therapeutics Announces Appointment of Marc Kozin as Vice Chairman of Board of Directors
October 13, 2020
From
GlobeNewswire News Releases
Dicerna to Present Nedosiran Data at American Society of Nephrology (ASN) Kidney Week 2020
October 09, 2020
Dicerna announced that clinical data on nedosiran, an investigational candidate for the treatment of PH, will be presented at ASN Kidney Week 2020.
From
Business Wire News Releases
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 01, 2020
Dicerna announced that the Company approved the grant of inducement stock options of common stock and restricted stock units among eight employees.
From
Business Wire News Releases
Dicerna to Participate in the Chardan 4th Annual Genetic Medicines Conference
September 28, 2020
Dicerna announced that Doug M. Fambrough will participate in a virtual fireside chat at the Chardan 4th Annual Genetic Medicines Conference on Oct. 5.
From
Business Wire News Releases
Dicerna Appoints Ling Zeng as Chief Legal Officer and Secretary
September 16, 2020
Dicerna announced the hiring of Ling Zeng, Esq., as the Company's chief legal officer and secretary and a member of the executive leadership team.
From
Business Wire News Releases
Dicerna to Participate in Upcoming September Investor Conferences
September 02, 2020
Dicerna announced that the Company will be participating in four virtual investor conferences in September.
From
Business Wire News Releases
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2020
Dicerna announced that the Company approved the grant of inducement stock options of common stock and restricted stock units among 11 employees.
From
Business Wire News Releases
Dicerna Announces Positive Clinical Data for Investigational Treatments RG6346 for Chronic Hepatitis B Virus and Nedosiran for Primary Hyperoxaluria, and Presents Preclinical Data Applying RNAi Techno
August 06, 2020
Dicerna presents positive clinical data for investigational treatments RG6346 for chronic HBV and Nedosiran for PH and preclinical data in new tissues
From
Business Wire News Releases
Dicerna Announces Second Quarter 2020 Financial Results and Provides a Business Update
August 06, 2020
Dicerna today reported its financial results for the second quarter ended June 30, 2020.
From
Business Wire News Releases
Dicerna Announces Appointment of Shreeram Aradhye, M.D., as Executive Vice President and Chief Medical Officer
August 05, 2020
Dicerna announced the appointment of Shreeram Aradhye, M.D., as the Company’s executive vice president and chief medical officer, effective Sept. 8.
From
Business Wire News Releases
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 03, 2020
Dicerna announced that the Company approved the grant of inducement stock options of common stock and restricted stock units among seven employees.
From
Business Wire News Releases
Dicerna to Report Second Quarter 2020 Financial Results and Host Virtual Research and Development Event on Aug. 6, 2020
July 24, 2020
Dicerna announced that it will release its Q2 2020 financial results before market open on Thurs., Aug. 6 and will host a virtual R&D Day event.
From
Business Wire News Releases
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2020
Dicerna announced that the Company approved the grant of inducement stock options of common stock and restricted stock units among 15 employees.
From
Business Wire News Releases
Dicerna Receives Rare Pediatric Disease Designation From U.S. Food and Drug Administration for Nedosiran for Treatment of Primary Hyperoxaluria
June 18, 2020
Dicerna announced that the U.S. FDA has granted rare pediatric disease designation for nedosiran, which is in development for PH types 1, 2 and 3.
From
Business Wire News Releases
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.